[{"address1": "175 Innovation Boulevard", "city": "Wilmington", "state": "DE", "zip": "19805", "country": "United States", "phone": "302 467 1280", "website": "https://preludetx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein, which along with SMARCA4 controls gene regulation through chromatin remodeling, which is in phase 1 clinical trial for the treatment of advanced or metastatic solid tumors; PRT7732, selective and orally bioavailable SMARCA2 degraders, which is in phase 1 multi-dose escalation trial for the treatment of advanced or metastatic solid tumors and; PRT2527, a Cyclin-dependent Kinase 9 inhibitor, which is in phase 1 dose-escalation and confirmation for the treatment of advanced solid tumors. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.", "fullTimeEmployees": 131, "companyOfficers": [{"maxAge": 1, "name": "Dr. Krishna  Vaddi D.V.M., Ph.D.", "age": 58, "title": "Founder, CEO & Director", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 905916, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Edna  Huang M.D.", "age": 51, "title": "President & Chief Medical Officer", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 865629, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bryant David Lim J.D.", "age": 52, "title": "CFO, Chief Legal Officer & Corporate Secretary", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 586425, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Aimee  Crombie Ph.D.", "title": "Senior VP and Head of Strategic Planning & Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Madhu  Pudipeddi Ph.D.", "title": "Senior Vice President of Technical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peggy A. Scherle Ph.D.", "age": 62, "title": "Chief Scientific Officer", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 868617, "exercisedValue": 0, "unexercisedValue": 436567}, {"maxAge": 1, "name": "Ms. Michele  Porreca M.B.A.", "title": "Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Andrew P. Combs Ph.D.", "age": 58, "title": "Executive VP & Chief Chemistry Officer", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 562461, "exercisedValue": 0, "unexercisedValue": 399432}, {"maxAge": 1, "name": "Mr. Naveen  Babbar Ph.D.", "title": "Senior Vice President of Translation Medicine", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. William B. Novotny M.D.", "title": "Senior Vice President of Clinical Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 10, "overallRisk": 9, "governanceEpochDate": 1743465600, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.6418, "open": 0.6554, "dayLow": 0.6459, "dayHigh": 0.7082, "regularMarketPreviousClose": 0.6418, "regularMarketOpen": 0.6554, "regularMarketDayLow": 0.6459, "regularMarketDayHigh": 0.7082, "payoutRatio": 0.0, "beta": 1.339, "forwardPE": -0.4690066, "volume": 165224, "regularMarketVolume": 165224, "averageVolume": 227079, "averageVolume10days": 284580, "averageDailyVolume10Day": 284580, "bid": 0.6623, "ask": 0.7126, "bidSize": 1, "askSize": 1, "marketCap": 39060488, "fiftyTwoWeekLow": 0.61, "fiftyTwoWeekHigh": 6.8, "priceToSalesTrailing12Months": 5.5800695, "fiftyDayAverage": 0.80586, "twoHundredDayAverage": 2.27338, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -78359624, "profitMargins": 0.0, "floatShares": 16841467, "sharesOutstanding": 42304400, "sharesShort": 2252233, "sharesShortPriorMonth": 3103542, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.040799998, "heldPercentInsiders": 0.09708, "heldPercentInstitutions": 0.8973, "shortRatio": 13.03, "shortPercentOfFloat": 0.129, "impliedSharesOutstanding": 56529600, "bookValue": 2.384, "priceToBook": 0.29706374, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -127173000, "trailingEps": -1.68, "forwardEps": -1.51, "enterpriseToRevenue": -11.194, "enterpriseToEbitda": 0.568, "52WeekChange": -0.8742451, "SandP52WeekChange": 0.059571505, "quoteType": "EQUITY", "currentPrice": 0.7082, "targetHighPrice": 5.0, "targetLowPrice": 1.0, "targetMeanPrice": 3.33333, "targetMedianPrice": 4.0, "recommendationMean": 2.25, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 133614000, "totalCashPerShare": 2.423, "ebitda": -137942000, "totalDebt": 18025000, "quickRatio": 5.211, "currentRatio": 5.3, "totalRevenue": 7000000, "debtToEquity": 13.711, "revenuePerShare": 0.092, "returnOnAssets": -0.38537, "returnOnEquity": -0.69013, "grossProfits": 7000000, "freeCashflow": -62002248, "operatingCashflow": -102888000, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -8.45775, "financialCurrency": "USD", "symbol": "PRLD", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "postMarketTime": 1744415072, "regularMarketTime": 1744401600, "exchange": "NMS", "marketState": "CLOSED", "regularMarketChangePercent": 10.345901, "regularMarketPrice": 0.7082, "shortName": "Prelude Therapeutics Incorporat", "longName": "Prelude Therapeutics Incorporated", "messageBoardId": "finmb_373775974", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "corporateActions": [], "postMarketChangePercent": -0.0141142, "postMarketPrice": 0.7081, "postMarketChange": -9.9957e-05, "regularMarketChange": 0.06639999, "regularMarketDayRange": "0.6459 - 0.7082", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 227079, "fiftyTwoWeekLowChange": 0.09819996, "fiftyTwoWeekLowChangePercent": 0.16098355, "fiftyTwoWeekRange": "0.61 - 6.8", "fiftyTwoWeekHighChange": -6.0918, "fiftyTwoWeekHighChangePercent": -0.8958529, "fiftyTwoWeekChangePercent": -87.42451, "earningsTimestamp": 1741606200, "earningsTimestampStart": 1746448200, "earningsTimestampEnd": 1746793800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.68, "epsForward": -1.51, "epsCurrentYear": -1.61933, "priceEpsCurrentYear": -0.43734133, "fiftyDayAverageChange": -0.097660005, "fiftyDayAverageChangePercent": -0.121187314, "twoHundredDayAverageChange": -1.5651801, "twoHundredDayAverageChangePercent": -0.6884815, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-09-25", "averageAnalystRating": "2.3 - Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1601040600000, "trailingPegRatio": null, "__fetch_time": "2025-04-12"}]